Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2003
11/06/2003WO2003090714A1 Method for the production of crystals, crystals obtained by said method, and use thereof in pharmaceutical formulations
11/06/2003WO2003090687A2 Using heat shock proteins to increase immune response
11/06/2003WO2003090686A2 Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
11/06/2003WO2003090684A2 Polymer compositions containing a macrocyclic triene compound
11/06/2003WO2003090681A2 SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-κB INHIBITORS AND ANTI-NEOPLASTIC AGENTS
11/06/2003WO2003090680A2 Novel phenyl derivatives as inducers of apoptosis
11/06/2003WO2003090672A2 2-(quinolonyl)-fused heterocycles as androgen receptor modulators
11/06/2003WO2003090667A2 Non-immunosuppressive imunogenic or vaccine composition comprising a mutated e7 protein of the hpv-16 virus
11/06/2003WO2003090665A2 Regulation of erythrocyte apoptosis
11/06/2003WO2003090664A2 Mutated hpv-16 e7 polypeptide, pharmaceutical composition comprising it and its preparation process
11/06/2003WO2003076458A3 Selective dipeptide inhibitors of kallikrein
11/06/2003WO2003075685A3 Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof
11/06/2003WO2003066889A3 Assay for acytyltransferase or deacetylase activity
11/06/2003WO2003057166A3 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003WO2003057007A3 System for monitoring bacterial tumor treatment
11/06/2003WO2003054009A3 Apoptotically active peptides
11/06/2003WO2003053999A3 Selective arylguanidine peptides as urokinase inhibitors
11/06/2003WO2003049694A3 Methods of therapy for non-hodgkin's lymphoma
11/06/2003WO2003039539A3 Use of endothelin receptor antagonists in the treatment of tumour diseases
11/06/2003WO2003035626A3 Azole derivatives and pharmaceutical compositions containing them
11/06/2003WO2003035004A3 Immunotherapy for reversing immune suppression
11/06/2003WO2003032903A3 Trisubstituted triazines compounds with antitubulin activity
11/06/2003WO2003032901A3 Pathological tissue detection and treatment employing targeted benzoindole optical agents
11/06/2003WO2003031939A3 Protein modification and maintenance molecules
11/06/2003WO2003030934A3 Cpg formulations and related methods
11/06/2003WO2003030908A3 Inhibitors of the egf receptor for the treatment of thyroid cancer
11/06/2003WO2003027263A3 Proteins associated with cell growth, differentiation, and death
11/06/2003WO2003018640A3 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids
11/06/2003WO2003016270A3 Selective estrogen receptor modulators
11/06/2003WO2003011878A3 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
11/06/2003WO2003007686A3 Use of copper chelators to inhibit the inactivation of protein c
11/06/2003WO2003004064A3 Products for treating ovarian cancers and for preventing relapses
11/06/2003WO2003003906A3 Diagnostic and screening methods for bladder cancer
11/06/2003WO2002098916A3 Transcriptional regulator of genes involved in the control of cell growth or cell proliferation. use of said regulator as a therapeutic or diagnostic agent
11/06/2003WO2002076979A8 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
11/06/2003WO2002072631A3 Mhc molecule constructs and their usesfor diagnosis and therapy
11/06/2003WO2002069950A3 Tumor treatement with a combination of a substrate of mrp5 and modulators of mrp5
11/06/2003WO2002062945A3 Compositions and methods relating to lung specific genes and proteins
11/06/2003WO2002061105A3 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc)
11/06/2003WO2002059558A8 Means and methods for treatment evaluation
11/06/2003WO2002057489A3 Method of determining a chemotherapeutic regimen based on ercc1 and ts expression
11/06/2003WO2002053742A3 Proteins and nucleic acids encoding same
11/06/2003WO2002046475A3 Method of detecting and treating tuberous sclerosis complex associated disorders
11/06/2003WO2002045708A9 Use of zwitterionic polysaccharides for the specific modulation of immune processes
11/06/2003WO2002034204A3 Calcilytic compounds
11/06/2003WO2002024891A9 B7-like molecules and uses thereof
11/06/2003WO2002004952A3 Diagnostic and therapeutic methods based on the l1 adhesion molecule for ovarian and endometrial tumors
11/06/2003WO2000026247A8 Ikaros isoforms and mutants
11/06/2003US20030208783 Transcriptional activator fusion proteins which comprises both tetracycline controlled transactivator proteins and reverse tetracycline transactivator proteins
11/06/2003US20030208780 Useful in preparing recombinant cells for diagnosis and therapy of human tumors
11/06/2003US20030208249 Energy-activated targeted cancer therapy
11/06/2003US20030208076 Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents
11/06/2003US20030208067 Inhibitors of protein kinase for the treatment of disease
11/06/2003US20030208058 B7-like polypeptides and polynucleotides
11/06/2003US20030208051 Human hepatocyte growth factor activator inhibitor homologue
11/06/2003US20030208048 Anti-alphavbeta3 recombinant human antibodies, nucleic acids encoding same and methods of use
11/06/2003US20030207937 Such as ethyl-2,2-4,4-tetramethyl-chroman-6-carboxylate; for retinoid-treatable conditions
11/06/2003US20030207936 Comprises fatty ester modified-polyoxyethylene glycol solubilizers
11/06/2003US20030207919 For treating, preventing, reducing inflammation, pain, fever,gastrointestinal disorders; decreasing gastrointestinal, renal and other toxicities resulting from use of nonsteroidal antiinflammatory drugs; multiplicity of compounds
11/06/2003US20030207909 Therapeutic acridone and acridine compounds
11/06/2003US20030207906 Chemical compounds
11/06/2003US20030207902 Heterocyclic compounds useful as inhibitors of tyrosine kinases
11/06/2003US20030207895 Tissue factor antagonists and methods of use thereof
11/06/2003US20030207887 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
11/06/2003US20030207883 Indazole benzimidazole compounds
11/06/2003US20030207881 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
11/06/2003US20030207879 Preferential G protein coupled receptor antagonists, such as 8-(3-amino-1-methyl-1H-pyrazol-5-yl)-1,3-dipropyl-3,7-dihydro -1H-purine-2,6-dione, used for prophylaxis of asthma, autoimmune diseases or retinopathy
11/06/2003US20030207878 Drugs used as angiogenesis inhibitors, vascular permeability or endothelial growth factor antagonists, for prophylaxis of cancer, diabetes, psoriasis, arthritis, autoimmune diseases, inflammation or scar formation
11/06/2003US20030207870 Aryl ureas with angiogenisis inhibiting activity
11/06/2003US20030207867 Method of treating a male or female animal in the treatment of a condition where inhibition of a cGMP-specific PDE is of a therapeutic benefit comprising treating said animal with an effective amount of a pharmaceutical composition with carriers
11/06/2003US20030207864 Novel arylsulfonanilide derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular
11/06/2003US20030207850 Hormone replacement therapy
11/06/2003US20030207846 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003US20030207842 Activity as non-covalent inhibitors of urokinase and having activity in reducing or inhibiting blood vessel formation are provided. These compounds have at a group having a guanidino moiety or derivative thereof. These compounds are useful for
11/06/2003US20030207841 Novel nucleoside and oligonucleotide analogues
11/06/2003US20030207834 The present invention relates to methods and compositions containing oligonucleotides suitable for administration to humans and other mammals.
11/06/2003US20030207829 methods for treating cancer by administering an effective amount of a modified Herpes simplex virus.
11/06/2003US20030207810 Method of treating malignancy associated hypercalcemia using active vitamin D analogues
11/06/2003US20030207794 Compounds which are alpha -halogenoacryloyl distamycin derivatives of formula (I) wherein R1 is a bromine or chlorine atom; R2 is a distamycin or distamycin-like framework as set forth in the specification; or a pharmaceutically acceptable
11/06/2003US20030207792 Screening for effective agents for the treatment of cancer which method comprises testing a putative agent that is likely to disrupt a critical normal gene product present in said cancer for its cytotoxic and/or growth inhibitory effect
11/06/2003US20030207449 Human ovarian mesothelial cells and methods of isolation and uses thereof
11/06/2003US20030207447 Used to distinguish between arterial endothelial cells (arteries) and venous endothelial cells (veins)
11/06/2003US20030207446 Infectious papillomavirus pseudoviral particles
11/06/2003US20030207434 Phosphodiesterases
11/06/2003US20030207403 For diagnosis or treatment of diseases with beta 10 polypeptides and alpha 2/ beta 10 heterodimers or their respective binding agents, such as thyroid gland disorders
11/06/2003US20030207347 Useful in treating ovarian, renal, neurological, cardiovascular disorders and modulating angiogenesis, cell proliferation
11/06/2003US20030207341 Methods for determining compounds capable of inhibiting the activities of the Ha-ras oncogene
11/06/2003US20030207318 Kinesin-like motor protein
11/06/2003US20030207299 Involves nucleic acid and amino acid sequences of human kinases; used in the diagnosis, treatment, and prevention of cancer, immune disorders, disorders affecting growth and development, cardiovascular diseases, and lipid disorders
11/06/2003US20030207293 Cryptic-like secreted protein
11/06/2003US20030207291 Human apoptosis-associated genes and human apoptosis-associated proteins produced thereby
11/06/2003US20030207263 Method of screening therapeutic agents
11/06/2003US20030207262 Compounds, methods of screening, and in vitro and in vivo uses involving anti-apoptotic genes and anti-apoptotic gene products
11/06/2003US20030206967 Sodium metasilicate, borax,sodium thiosulfate, potassium carbonate, refined cane sugar and water; improvement in disease resistance, weight gain rate, crop yield, crop quality, and harvest time
11/06/2003US20030206923 Combination of soybean, mushroom and mung bean provides phytoestrogens, beta-glucans, saponins, inositol hexaphosphate, and lectins.
11/06/2003US20030206917 Transferring a protein to a cell by coating the cell surface with a lipidated protein; and contacting said cell with a fusion protein having affinity for said lipidated protein and capable of binding to a cell surface receptor
11/06/2003US20030206910 Poloxamer 188, Poloxamer 237, Poloxamer 338, Poloxamer 124, Poloxamer 401, Tetronic 904, Tetronic 908, Tetronic 1107 or Tetronic 90R4; especially for treating chronic hepatitis and cancer
11/06/2003US20030206908 Human paris-1 antigen and nucleic acids: diagnostic and therapeutic uses
11/06/2003US20030206903 Combination therapies for B-cell lynphomas comprising administration of anti-CD20 antibody
11/06/2003US20030206898 Use of anti-TNFalpha antibodies and another drug
1 ... 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 ... 2211